10-K: Leap Therapeutics Reports Full Year 2024 Results and Provides Business Update

Leap Therapeutics' 10-K filing summarizes the company's financial performance for 2024 and provides updates on its clinical development programs, including sirexatamab and FL-501.

Summary

• Leap Therapeutics, Inc. is a biopharmaceutical company focused on developing biomarker-targeted antibody therapies for cancer treatment.
• The company's lead drug candidate is sirexatamab (DKN-01), a monoclonal antibody inhibiting Dickkopf-related protein 1 (DKK1), currently in clinical trials for colorectal cancer.
• Leap also has a preclinical program, FL-501, a monoclonal antibody inhibiting the GDF-15 protein.
• The company's strategy involves identifying, acquiring, and developing molecules that can be rapidly translated into impactful therapeutics.
• Leap reported a net loss of $67.6 million for the year ended December 31, 2024, and an accumulated deficit of $467.4 million.
• Research and development expenses totaled $57.2 million for 2024.
• As of December 31, 2024, Leap had $47.2 million in cash and cash equivalents, which it believes will fund operations for at least the next 12 months.
• The company is pursuing additional capital through equity offerings, debt financings, and strategic collaborations.
• Leap is dependent on third-party contract manufacturers (CMOs) for the production of clinical trial material.
• The company's commercial success depends on obtaining and maintaining patent protection for its technologies and products.
• Leap's common stock is listed on the Nasdaq Capital Market under the symbol LPTX.
• The company received a letter from Nasdaq stating that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the Closing Bid Price Rule) because its common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While Leap has promising clinical programs and sufficient cash for the near term, it is experiencing significant losses and faces challenges in raising capital and maintaining its Nasdaq listing. The overall sentiment is cautiously negative.

Positives

• Leap has a lead clinical-stage program, sirexatamab (DKN-01), in development for colorectal cancer.
• The company has a preclinical program, FL-501, targeting GDF-15.
• Leap believes its cash and cash equivalents will fund operations for at least the next 12 months.
• The company is actively pursuing additional capital and strategic collaborations.

Negatives

• Leap reported a significant net loss of $67.6 million for 2024 and has an accumulated deficit of $467.4 million.
• The company has no products approved for sale and has not generated any revenue from product sales.
• Leap is dependent on third-party contract manufacturers (CMOs) for the production of clinical trial material.
• The company received a letter from Nasdaq stating that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the Closing Bid Price Rule) because its common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days.

Risks

• Leap's clinical trials may not be successful, and regulatory approvals may be delayed or not obtained.
• The company faces substantial competition from larger pharmaceutical and biotechnology companies.
• Leap's reliance on third-party CMOs and CROs poses risks to its development and commercialization efforts.
• The company may not be able to raise additional capital when needed or on attractive terms.
• Leap's intellectual property rights may be inadequate to protect its technology and product candidates.
• The company's share price has been low and volatile, and it could be subject to securities class action litigation.
• Leap's failure to maintain compliance with Nasdaq's continued listing requirements could result in the delisting of its common stock.

Future Outlook

Leap expects to continue incurring significant expenses and operating losses for at least the next several years as it continues the development of its product candidates, seeks regulatory approvals, outsources manufacturing, and expands its operations.

Industry Context

The biotechnology and pharmaceutical industries are characterized by continuing technological advancement and significant competition. Leap faces competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions.

Comparison to Industry Standards

• Novartis, Merck, Amgen, Pfizer, Junshi Biosciences and Twist Biosciences are all currently developing or have previously been developing anti-DKK1 monoclonal antibodies.
• Pfizer, CatalYm, NGM Biosciences, among other companies, are all currently developing or have developed antibodies targeting GDF-15.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings and potential losses due to stock price volatility.
• Employees are subject to an insider trading policy and may be affected by potential cost-cutting measures.
• Customers (potential patients) may benefit from the development of new cancer therapies.
• Suppliers and creditors face the risk of non-payment if Leap's financial condition deteriorates.

Next Steps

• Continue the development of sirexatamab and FL-501.
• Seek regulatory approvals for product candidates.
• Outsource the manufacturing of product candidates.
• Contract with third parties for sales, marketing, and distribution.
• Maintain, expand, and protect the intellectual property portfolio.
• Continue research and development efforts.
• Add operational, financial, and management information systems and personnel.

Key Dates

Keywords

sirexatamab, DKN-01, FL-501, colorectal cancer, clinical trials, biopharmaceutical, antibody therapies, research and development, financial results, Leap Therapeutics